<DOC>
	<DOCNO>NCT00846703</DOCNO>
	<brief_summary>The Guangdong work group childhood acute lymphoblastic leukemia ( ALL ) therapy set October 2002 . The investigator treat childhood ALL GZ2002 protocol since year 2002 , protocol mainly derive ALLIC-BFM 2002 protocol . After summarize last six year ' experience , group revise GZ2002 ALL protocol year 2008 , name GD-2008 ALL protocol . The diagnosis classify criterion accord ALLIC-BFM 2002 protocol , chemotherapy protocol consist therapeutic phase ALLIC-BFM 2002 protocol prescribe .</brief_summary>
	<brief_title>The GD-2008 ALL Protocol Childhood Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>The modification include : 1 . In induction phase , agent dexamethasone 6 mg/m2 use instead prednisone prednisone prophase . 2 . The phase `` CAM '' 2 week SR patient 4 week IR HR patient , respectively . 3 . Both SR IR treatment involve protocol mM /M ( 8 week ) phase consolidation . However , folinic acid rescue start 36 hour instead 42 hour . The type HR enters block treatment BFM protocol . 4 . There randomize study delay intensification . The GD-2008 ALL protocol us protocol II BFM study . 5 . The randomized study focus phase maintenance . The maintenance A BFM protocol , maintenance B consist 6mp/MTX VCR/ dexamethasone . The cycle 8 week : VCR d1 , Dexamethasone d2 d7 , 6mp d8 d56 , MTX d9 , d16 , d23 , d30 , d37 , d44 , d51 . 6 . The GD-2008 ALL protocol HR patient use re-blocks protocol II phase .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Cytologically proven acute lymphoblastic leukemia ( ALL ) No relapse previously unrecognized ALL Patients must meet one follow risk criterion : Standardrisk ( SR ) group meet follow criterion : Blasts &lt; 1,000/μL peripheral blood ( PB ) day 8 Aged 1 &lt; 6 year Initial WBC &lt; 20,000/μL M1 ( 5 % ) M2 ( ≥ 5 % &lt; 25 % ) blast bone marrow day 15 ; M1 marrow day 33 . Intermediaterisk ( IR ) group meet follow criterion : Aged &lt; 1 ≥ 6 year and/or WBC ≥ 20,000/μL Blasts &lt; 1,000/μL PB day 8 M1 M2 marrow day 15 M3 ( ≥ 25 % ) marrow day 15 OR meet SR criterion M3 marrow day 15 *M1 marrow day 33 . Highrisk ( HR ) group meet ≥ 1 follow criterion : Meets IR criterion M3 marrow day 15 ( SR M3 day 15 ) Blasts ≥ 1,000/μL PB day 8 M2 M3 marrow day 33 Translocation ( 9 ; 22 ) [ BCR/ABL+ ] ( Philadelphia chromosomepositive ) ( 4 ; 11 ) [ MLL/AF4+ ] . No Down syndrome No major disease prohibits study treatment ( e.g. , severe congenital heart disease ) Not require significant therapy modification owe study therapy associate complication No complication due intervention No one miss data need differential diagnosis , selection proper therapy arm</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>